Advertisement
U.S. markets open in 1 hour 56 minutes

Oncolytics Biotech Inc. (ONC.TO)

Toronto - Toronto Real Time Price. Currency in CAD
1.4200+0.0800 (+5.97%)
At close: 03:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3400
Open1.3600
Bid1.4100 x 0
Ask1.4300 x 0
Day's Range1.3200 - 1.4300
52 Week Range1.2000 - 4.4900
Volume97,658
Avg. Volume81,131
Market Cap107.096M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-0.4100
Earnings DateMay 03, 2024 - May 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.56
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ONC.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Insider Monkey

      Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

      Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript March 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Oncolytics Biotech’s Fourth Quarter and Full Year 2023 Conference Call. All participants […]

    • CNW Group

      Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

      Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

    • Newsfile

      Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

      Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.Read the full article on Investoorideas.com Research Nester says, "The global pancreatic cancer market size is slated to expand at ~